Novel Antipsychotic Use in Schizophrenia
J Clin Psychiatry 2000;61(3):223-232
© Copyright 2017 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
It is now 100 years since the concept
of dementia praecox was first proposed
by Kraepelin and then renamed
schizophrenia by Bleuler. In his later
writings, Kraepelin made it clear that
he regarded it as a provisional category.
Sadly, we are still stuck with
this provisional category, said Professor
Robin Murray in his presentation.